Diagnostic Accuracy of Image-guided Biopsies for Diagnosis of Metastatic Melanoma in a Real-life Setting.
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
13 Dec 2022
13 Dec 2022
Historique:
entrez:
13
12
2022
pubmed:
14
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Early detection of melanoma metastasis is essential in order to initiate treatment and improve patient prognosis. The aim of this study was to determine the diagnostic accuracy of different image-guided biopsy techniques in patients with melanoma. A cohort study of patients diagnosed with melanoma who had undergone image-guided biopsies (ultrasound-guided fine-needle aspiration cytology, ultrasound-guided core-needle biopsy, computerized tomography--guided fine-needle aspiration cytology and computerized tomography-guided core-needle biopsy) to detect melanoma metastasis between 2004 and 2021 was conducted. The reference standard was histological confirmation and/or clinical-radiological follow-up. Sensitivity, specificity, positive and negative predictive values were calculated. A total of 600 image--guided biopsies performed on 460 patients were included for analysis. Locoregional lesions represented 459 (76.5%) biopsies, and 141 (23.5%) were distant lesions. Of the included biopsies, 49 (8.2%) were insufficient for diagnosis. Overall, sensitivity and specificity were 92% (95% confidence interval 89-94) and 96% (95% confidence interval 91-99), respectively. Sensitivity sub-analyses revealed lower diagnostic accuracy values in the lung, inguinal lymph nodes, and computerized tomography-guided lesions under 1 cm. Limitations include spontaneous metastasis regression and arbitrary minimum follow-up period. Image-guided biopsies in patients with melanoma have high sensitivity and specificity for detection of regional or distant metastasis. Tissue type, location and tumour burden may influence the diagnostic accuracy of the test.
Identifiants
pubmed: 36511331
doi: 10.2340/actadv.v102.3981
pmc: PMC9811304
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00833Références
JAMA Oncol. 2019 Feb 1;5(2):187-194
pubmed: 30422243
Am J Clin Pathol. 2007 Mar;127(3):385-97
pubmed: 17276948
J Am Acad Dermatol. 2016 Sep;75(3):516-524
pubmed: 27183845
Cancer. 2000 Jun 25;90(3):162-6
pubmed: 10896329
Lancet Oncol. 2010 Apr;11(4):391-400
pubmed: 20106719
N Engl J Med. 2017 Jun 8;376(23):2211-2222
pubmed: 28591523
J Invest Dermatol. 2016 Jun;136(6):1161-1171
pubmed: 26902923
BMJ Open. 2016 Nov 14;6(11):e012799
pubmed: 28137831
J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):403-8
pubmed: 9091471
Am J Clin Pathol. 2013 Nov;140(5):635-42
pubmed: 24124141
J Natl Cancer Inst. 1986 Nov;77(5):1013-21
pubmed: 3464794
Br J Dermatol. 2006 Sep;155(3):552-6
pubmed: 16911280
Cancer. 2001 Aug 25;93(4):263-8
pubmed: 11507700
J Am Acad Dermatol. 2019 Dec;81(6):1330-1338
pubmed: 31163236
Melanoma Res. 2015 Dec;25(6):519-27
pubmed: 25933210
Radiol Med. 2010 Jun;115(4):612-8
pubmed: 20177981
Diagn Cytopathol. 2002 May;26(5):334-9
pubmed: 11992379
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancer. 2000 Jun 25;90(3):186-93
pubmed: 10896332
Melanoma Res. 2009 Oct;19(5):275-82
pubmed: 19633580
J Natl Cancer Inst. 2011 Dec 7;103(23):1771-7
pubmed: 21940673
J Am Acad Dermatol. 2000 May;42(5 Pt 1):735-40
pubmed: 10775847